UBS Group’s Lyra Therapeutics LYRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18 | Sell |
2
-8,683
| -100% | -$78.1K | ﹤0.01% | 8799 |
|
|
2025
Q1 | $54.7K | Buy |
8,685
+186
| +2% | +$1.17K | ﹤0.01% | 6234 |
|
|
2024
Q4 | $87.5K | Buy |
8,499
+8,001
| +1,607% | +$82.4K | ﹤0.01% | 5746 |
|
|
2024
Q3 | $6.4K | Buy |
498
+204
| +69% | +$2.62K | ﹤0.01% | 6763 |
|
|
2024
Q2 | $4.07K | Buy |
+294
| New | +$4.07K | ﹤0.01% | 6973 |
|
|
2024
Q1 | – | Sell |
-96
| Closed | -$25.2K | – | 7650 |
|
|
2023
Q4 | $25.2K | Buy |
+96
| New | +$25.2K | ﹤0.01% | 5754 |
|
|
2023
Q3 | – | Hold |
0
| – | -$74 | – | 7806 |
|
|
2023
Q2 | – | Sell |
-17
| Closed | -$1.71K | – | 7466 |
|
|
2023
Q1 | $1.71K | Sell |
17
-51
| -75% | -$5.14K | ﹤0.01% | 7565 |
|
|
2022
Q4 | $10.7K | Buy |
68
+6
| +10% | +$941 | ﹤0.01% | 7287 |
|
|
2022
Q3 | $15K | Buy |
62
+22
| +55% | +$5.32K | ﹤0.01% | 6712 |
|
|
2022
Q2 | $11K | Buy |
+40
| New | +$11K | ﹤0.01% | 6786 |
|
|
2022
Q1 | – | Sell |
-81
| Closed | -$18K | – | 9418 |
|
|
2021
Q4 | $18K | Buy |
+81
| New | +$18K | ﹤0.01% | 6862 |
|
|
2021
Q3 | – | Sell |
-11
| Closed | -$5K | – | 8592 |
|
|
2021
Q2 | $5K | Sell |
11
-44
| -80% | -$20K | ﹤0.01% | 7445 |
|
|
2021
Q1 | $32K | Sell |
55
-17
| -24% | -$9.89K | ﹤0.01% | 5944 |
|
|
2020
Q4 | $41K | Buy |
72
+55
| +324% | +$31.3K | ﹤0.01% | 5363 |
|
|
2020
Q3 | $9K | Sell |
17
-17
| -50% | -$9K | ﹤0.01% | 6060 |
|
|
2020
Q2 | $19K | Buy |
+34
| New | +$19K | ﹤0.01% | 5744 |
|